MA26581A1 - Forme hydratee nouvelle d'un derive de thiazolidine-dione, procede pour sa preparation et composition pharmaceutique la contenant - Google Patents

Forme hydratee nouvelle d'un derive de thiazolidine-dione, procede pour sa preparation et composition pharmaceutique la contenant

Info

Publication number
MA26581A1
MA26581A1 MA25391A MA25391A MA26581A1 MA 26581 A1 MA26581 A1 MA 26581A1 MA 25391 A MA25391 A MA 25391A MA 25391 A MA25391 A MA 25391A MA 26581 A1 MA26581 A1 MA 26581A1
Authority
MA
Morocco
Prior art keywords
thiazolidine
preparation
pharmaceutical composition
composition containing
same
Prior art date
Application number
MA25391A
Other languages
English (en)
Inventor
Bernadette Marie Choudary
Mr Ian Robert Lynch
Michael John Sasse
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MA26581A1 publication Critical patent/MA26581A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA25391A 1997-12-16 1998-12-14 Forme hydratee nouvelle d'un derive de thiazolidine-dione, procede pour sa preparation et composition pharmaceutique la contenant MA26581A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9726563.1A GB9726563D0 (en) 1997-12-16 1997-12-16 Novel pharmaceutical

Publications (1)

Publication Number Publication Date
MA26581A1 true MA26581A1 (fr) 2004-12-20

Family

ID=10823691

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25391A MA26581A1 (fr) 1997-12-16 1998-12-14 Forme hydratee nouvelle d'un derive de thiazolidine-dione, procede pour sa preparation et composition pharmaceutique la contenant

Country Status (37)

Country Link
US (4) US20020133016A1 (fr)
EP (1) EP1042321A1 (fr)
JP (1) JP2002508371A (fr)
KR (1) KR100549141B1 (fr)
CN (3) CN101318956A (fr)
AP (1) AP1363A (fr)
AR (2) AR017211A1 (fr)
AU (2) AU2272299A (fr)
BG (1) BG64850B1 (fr)
BR (1) BR9813598A (fr)
CA (1) CA2314967A1 (fr)
CO (1) CO4990943A1 (fr)
CZ (1) CZ300081B6 (fr)
DZ (1) DZ2679A1 (fr)
EA (1) EA002833B1 (fr)
EG (1) EG22250A (fr)
GB (1) GB9726563D0 (fr)
HR (1) HRP20000404A2 (fr)
HU (1) HUP0102292A3 (fr)
ID (1) ID24714A (fr)
IL (2) IL136425A (fr)
MA (1) MA26581A1 (fr)
MY (1) MY128573A (fr)
NO (1) NO317255B1 (fr)
NZ (1) NZ504703A (fr)
OA (1) OA11900A (fr)
PE (1) PE20000125A1 (fr)
PL (1) PL341213A1 (fr)
RS (1) RS50080B (fr)
SA (1) SA99200200B1 (fr)
SK (1) SK286422B6 (fr)
TR (2) TR200001793T2 (fr)
TW (1) TW487709B (fr)
UA (1) UA66821C2 (fr)
UY (2) UY25309A1 (fr)
WO (1) WO1999031093A1 (fr)
ZA (1) ZA9811504B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB9726568D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US20020137940A1 (en) * 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9909041D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
OA11871A (en) * 1999-04-23 2006-03-27 Smithkline Beecham Plc Novel pharmaceutical.
PE20010045A1 (es) * 1999-04-23 2001-03-10 Smithkline Beecham Plc Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidin-2,4-diona
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
ES2203453T3 (es) * 1999-04-23 2004-04-16 Smithkline Beecham Plc Polimorfo de sal del acido maleico de 5-(4-(2-(n-metil-n-(2-piridil)amino)etoxi)bentil)tiazolidina-2,4-diona.
GB0014005D0 (en) * 2000-06-08 2000-08-02 Smithkline Beecham Plc Novel pharmaceutical
GB0021784D0 (en) * 2000-09-05 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0021978D0 (en) * 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
WO2003050112A1 (fr) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Hydrates de toluenesulfonate d'un derive de thiazolidinedione
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
KR100450700B1 (ko) * 2002-03-22 2004-10-01 주식회사종근당 티아졸리딘디온 유도체 화합물 및 이를 함유하는 약제학적조성물
EP1468997A3 (fr) * 2003-04-18 2004-11-03 CHEMI S.p.A. Formes polymorphes de maléate de rosiglitatone
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
WO2005065654A2 (fr) * 2003-12-31 2005-07-21 Alpharma, Inc. Preparations de rosiglitazone
US20050163842A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone and metformin formulations
ITMI20041537A1 (it) * 2004-07-28 2004-10-28 Chemi Spa Nuova forma polimorfa del rosiglitazone maleato
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
US7435741B2 (en) * 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
EP2184055A1 (fr) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Procédé de préparation de formes galéniques solides de maléate de rosiglitazone

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842925A1 (fr) * 1987-09-04 1998-05-20 Beecham Group Plc Thiazolidinédiones substituées
US6288095B1 (en) * 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
GB8820389D0 (en) * 1988-08-26 1988-09-28 Beecham Group Plc Novel compounds
GB9124513D0 (en) * 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
US5741803A (en) * 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
SG47100A1 (en) * 1994-02-10 1998-03-20 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases
DE4404198A1 (de) 1994-02-10 1995-08-17 Henkel Kgaa 2-Fluor-6-nitroaniline
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
EP1322647A1 (fr) 2000-09-26 2003-07-02 Dr. Reddy's Research Foundation Nouvelles formes polymorphes de 5- 4- 2- n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate et procede de preparation associe

Also Published As

Publication number Publication date
YU36400A (sh) 2003-12-31
IL136425A (en) 2004-08-31
AU770818B2 (en) 2004-03-04
US20030139604A1 (en) 2003-07-24
DZ2679A1 (fr) 2003-03-29
UA66821C2 (uk) 2004-06-15
HUP0102292A3 (en) 2003-12-29
EP1042321A1 (fr) 2000-10-11
GB9726563D0 (en) 1998-02-11
PL341213A1 (en) 2001-03-26
CZ300081B6 (cs) 2009-01-28
AP1363A (en) 2005-01-21
US20020133016A1 (en) 2002-09-19
US20070037859A1 (en) 2007-02-15
CZ20002206A3 (cs) 2000-12-13
TR199802624A2 (xx) 1999-10-21
UY25306A1 (es) 2000-12-29
RS50080B (sr) 2009-01-22
US20050288513A1 (en) 2005-12-29
EA002833B1 (ru) 2002-10-31
WO1999031093A1 (fr) 1999-06-24
HRP20000404A2 (en) 2000-12-31
ZA9811504B (en) 2000-06-15
AU2753802A (en) 2002-05-16
IL136425A0 (en) 2001-06-14
CA2314967A1 (fr) 1999-06-24
SK286422B6 (sk) 2008-09-05
ID24714A (id) 2000-08-03
PE20000125A1 (es) 2000-03-03
KR20010033140A (ko) 2001-04-25
AR016161A1 (es) 2001-06-20
AU2272299A (en) 1999-07-05
CN101318957A (zh) 2008-12-10
BG104606A (en) 2001-02-28
NO20003070D0 (no) 2000-06-15
CN101318956A (zh) 2008-12-10
JP2002508371A (ja) 2002-03-19
KR100549141B1 (ko) 2006-02-03
UY25309A1 (es) 1999-07-19
SK9182000A3 (en) 2000-12-11
NO20003070L (no) 2000-06-15
NZ504703A (en) 2002-12-20
TR199802624A3 (tr) 1999-10-21
SA99200200B1 (ar) 2006-11-11
IL160847A0 (en) 2004-08-31
US7368574B2 (en) 2008-05-06
AR017211A1 (es) 2001-08-22
MY128573A (en) 2007-02-28
EA200000656A1 (ru) 2000-12-25
NO317255B1 (no) 2004-09-27
HUP0102292A2 (hu) 2002-05-29
TW487709B (en) 2002-05-21
OA11900A (en) 2006-04-10
EG22250A (en) 2002-11-30
CO4990943A1 (es) 2000-12-26
AP2000001829A0 (en) 2000-06-30
CN1285831A (zh) 2001-02-28
BR9813598A (pt) 2000-10-10
TR200001793T2 (tr) 2000-10-23
BG64850B1 (bg) 2006-06-30

Similar Documents

Publication Publication Date Title
MA26581A1 (fr) Forme hydratee nouvelle d'un derive de thiazolidine-dione, procede pour sa preparation et composition pharmaceutique la contenant
MA23942A1 (fr) Formulation nouvelle contenant de la paroxetine, et procede pour sa preparation
FR2531087B1 (fr) Nouvelle forme d'ester de cefuroxime, procede pour sa preparation et composition pharmaceutique la contenant
MA26415A1 (fr) Composes heterocycliques, procede pour la preparation et compositions pharmaceutiques les contenant
MA26571A1 (fr) Derives d'acide hydroxamique, compositions pharmaceutiques les contenant et procede pour leur preparation
MA24469A1 (fr) Derives d'acide arylsulfonyhydroxamique, procede pour leur preparation et compositions les contenant
MA26430A1 (fr) 4 (3h)-quinazolinones 2,3-disubstituees nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26516A1 (fr) Tartrate d'un dipeptide substitue, procede pour sa preparation et compositions pharmaceutiques le contenant.
MA26687A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26471A1 (fr) Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2740136B1 (fr) Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
FR2650182B1 (fr) Procede de preparation d'une composition pharmaceutique sous forme de microparticules
FR2670488B1 (fr) Composition pharmaceutique contenant une forme physique particuliere d'un amide heterocyclique et son procede de preparation.
MA22819A1 (fr) Procede de preparation d'un nouveau produit pharmaceutique.
MA26519A1 (fr) Derives d'azetidinylpropylpiperidine, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2707554B1 (fr) Bloc d'impression offset et procédé pour sa fabrication.
FR2569702B1 (fr) Nouvelle 4'-deschlororebeccamycine, composition pharmaceutique la contenant et procede pour sa preparation
MA26582A1 (fr) Derives de thiazolidinedione nouveau, procede pour sa preparation et composition pharmaceutique le contenant
FR2749504B1 (fr) Composition de suspension pour produit cosmetique et procede d'utilisation de celui-ci
MA22443A1 (fr) Procede de preparation d'une composition pharmaceutique .
MA26708A1 (fr) Derive d'indole nouveau, procede pour sa preparation et compositions pharmaceutiques le contenant
MA24534A1 (fr) Procede pour la production d'irones
FR2736908B1 (fr) Procede d'epuration des solutions d'aluminate de sodium contenant de l'oxalate de sodium
MA23798A1 (fr) Procede de preparation de nouvelle composition pharmaceutique contenant la trimebutine
FR2754710B1 (fr) Procede de preparation d'une forme pharmaceutique multiparticulaire a liberation controlee plurisequentielle